IBM Watson: Mixed Signals from the Real World and IBM Marketers

February 21, 2017

I read a write up which might be fake news for all I know. I live in rural Kentucky and the doings of folks in a big city like Houston are mysterious and far away. Out local doctor squeezes in humans after dealing with race horses and dogs.

I read in Forbes, the capitalist tool, this story: “MD Anderson Benches IBM Watson In Setback For Artificial Intelligence In Medicine.”

The main idea is easy to grasp, even for folks like me sitting near the wood stove in Harrod’s Creek. As I understand it, IBM Watson was supposed to be helping the doctors at the número uno cancer treatment center in their quest to eradicate cancer. I assume the idea was to make more time available to physicians and other health care givers because IBM Watson would have had answers about patient treatment. IBM Watson knew the Jeopardy answers, right. Dealing with cancer-related questions seems to me to be easier: More narrow domain, more consistent terminology, smart people, etc etc.

The possibly fake news write up says:

The partnership between IBM and one of the world’s top cancer research institutions is falling apart. The project is on hold, MD Anderson confirms, and has been since late last year. MD Anderson is actively requesting bids from other contractors who might replace IBM in future efforts. And a scathing report from auditors at the University of Texas says the project cost MD Anderson more than $62 million and yet did not meet its goals.

But there is good news, or at least face saving news. I like this statement in the capitalist tool:

The report, however, states: “Results stated herein should not be interpreted as an opinion on the scientific basis or functional capabilities of the system in its current state.”

The door is not locked. Perhaps IBM Watson will once again be allowed to dine in the MD Anderson cafeteria and spark the pixels on the MD Anderson computing devices. Every smart software cloud may have a silver lining. Right?

But the project seems to be on “hold.” If the news is fake, then the project is full steam ahead, but I think the truth is closer to something like this: The users found the system like other smart software. Sort of helpful sometimes. At other times, the smart software was adding work, time, and frustration to an already high pressure, high stakes environment.

The capitalist tool ventures this observation:

The disclosure comes at an uncomfortable moment for IBM. Tomorrow, the company’s chief executive, Ginni Rometty, will make a presentation to a giant health information technology conference detailing the progress Watson has made in health care, and announcing the launch of new products for managing medical images and making sure hospitals deliver value for the money, as well as new partnerships with healthcare systems. The end of the MD Anderson collaboration looks bad.

I have zero idea what giant conference is held “tomorrow.” But I did notice this write up, which may be a coincidence: “IBM Sees Watson As a Primary Care Provider’s Assistant.” This seems similar to what IBM Watson was going to do at the MD Anderson cancer center. The write up asserts:

IBM is prepping Watson to work alongside primary care physicians and streamline processes. The company also added features to its Watson-based health cloud services.

The IBM Watson system has been enhanced too. The write up reports:

That Watson-primary care provider connection is being rolled out in Central New York in a six-county region and more than 2,000 providers. Meanwhile, Atrius Health, based in Massachusetts, will embed IBM’s cognitive computing tools inside its electronic medical records workflow for primary care providers.

This sounds good. Perhaps this is the “real” IBM Watson news. Rapid adoption and new capabilities make IBM Watson a must have in the smart health care providers arsenal of disease fighting weapons.

But there is that MD Anderson situation.

What do I make of these apparently contradictory write ups, which I assume are fake news, of course?

  1. IBM Watson, like other end user smart software systems, is a disappointment in actual use. Humans have to learn how to use the system and then take time to figure out which of the outputs are the ones that are likely to be useful in a particular patient’s case. Instead of saving time, the smart software adds tasks to already stretched professionals.
  2. The marketing and sales pressure is great. As a result, the marketers’ explanations may not match up with the engineering realities of a search-based system. When the marketers have left the building, the users learn the reality. After normal bureaucratic jabbering, the users’ dissatisfaction become too much for administrators to deal with. Hasta la vista, Sr. Watson.
  3. IBM, like other outfits betting on smart software, continue to repeat the cycle of belief, hyperbolic marketing, and learning about the costs and problems the smart system triggers. So why did Fast Search & Transfer’s run to fame fall off a cliff? Why is Hewlett Packard annoyed with Autonomy Software? Why did Entopia fail? Why is Lexmark’s new owners trying to exit the search with smart software business? Answer: Hope does not make an end user facing smart system generate sustainable revenues.

Because this IBM Watson news is fake. Why worry? Smart software will lift IBM to heights not experienced since the mainframe was the go to solution to computing needs. If you have a z series, you can run IBM Watson on it. Now that’s something I wish I could experience. My hunch is that none of the docs at MD Anderson will buy a z series and load up Watson because it is so darned useful. Maybe that is the “real” reality?

How does IBM get this Watson thing under control and generating money and producing happy customers? Let’s ask Watson? On the other hand, I don’t think the outputs will be too helpful.

Stephen E Arnold, February 21, 2017

Comments

Comments are closed.

  • Archives

  • Recent Posts

  • Meta